Removal of hepatitis virus infectivity from clotting factor concentrates

Viral hepatitis

Recent research has led to a greater understanding of the mechanisms and management of the various forms of viral hepatitis. The clinician can rapidly arrive at a precise diagnosis using serologic markers to complement epidemiologic data. In addition, effective immunoprophylaxis is possible; thus, disease spread can be minimized.

Hepatitis B virus infection in multitransfused haemophiliacs

A longitudinal study of 44 haemophilic children, all in a treatment programme with factor concentrates, was undertaken to evaluate the occurrence, characteristics, and evolution of hepatitis B virus (HBV) infection. Twenty four children (55%) (group I) showed signs of HBV infection, while 20 (45%) (group II) did not. Age at onset of treatment, number of infusions, and total amount of concentrate received did not show significant differences between the two groups. In group I only four children (16%) had symptomatic acute hepatitis. Chronic liver disease was present in nine patients (38% of infected children). The early age of infection would seem to be an important factor for predicting chronic evolution. Evidence of delta infection in three children with severe liver disease seemed to confirm the high pathogenicity of this agent. Because of the risks associated with chronic HBV infection a careful follow up of patients positive for hepatitis B surface antigen is mandatory.